Banque Cantonale Vaudoise Raises Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Posted by Brian Himes on May 21st, 2026

Banque Cantonale Vaudoise increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 36.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,966 shares of the company’s stock after purchasing an additional 1,603 shares during the quarter. Banque Cantonale Vaudoise’s holdings in IDEXX Laboratories were worth $4,037,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its stake in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares during the last quarter. CWA Asset Management Group LLC lifted its stake in shares of IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after purchasing an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. lifted its stake in shares of IDEXX Laboratories by 1.7% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after purchasing an additional 18 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in shares of IDEXX Laboratories by 11.5% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after purchasing an additional 18 shares during the last quarter. Finally, Rockland Trust Co. lifted its stake in shares of IDEXX Laboratories by 4.4% during the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the sale, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. This represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the sale, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,777 shares of company stock worth $18,235,113 over the last three months. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Up 1.3%

Shares of IDXX stock opened at $553.58 on Thursday. The stock’s 50-day simple moving average is $568.24 and its 200-day simple moving average is $643.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market capitalization of $43.67 billion, a PE ratio of 40.76, a P/E/G ratio of 3.17 and a beta of 1.58. IDEXX Laboratories, Inc. has a fifty-two week low of $496.61 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Citigroup assumed coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Barclays decreased their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Piper Sandler reduced their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

Get Our Latest Stock Analysis on IDXX

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.